Letermovir Patent Expiration
Letermovir was first introduced by Merck Sharp And Dohme Corp
Letermovir Patents
Given below is the list of patents protecting Letermovir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Prevymis | US10603384 | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative | Feb 28, 2033 | Merck Sharp Dohme |
| Prevymis | USRE46791 | Substituted dihydroquinazolines | Jan 18, 2029 | Merck Sharp Dohme |
| Prevymis | USRE46791 | Substituted dihydroquinazolines | Jan 18, 2029 | Msd |
| Prevymis | US7196086 | Substituted dihydroquinazolines |
May 22, 2024
(Expired) | Merck Sharp Dohme |
| Prevymis | US8513255 | Substituted dihydroquinazolines |
May 22, 2024
(Expired) | Merck Sharp Dohme |
Letermovir's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List